177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the use of 177Lu-PP-F11N for imaging and therapy of
patients with advanced medullary thyroid carcinoma (MTC). 177Lu-PP-F11N is a gastrin
analogon, binding to cholecystokinin-2 receptors. This receptors show an overexpression on
more than 90 % of medullary thyroid carcinomas.
Phase:
Early Phase 1
Details
Lead Sponsor:
University Hospital, Basel, Switzerland
Collaborators:
Center for Proton Therapy, Paul Scherrer Institute, Villigen,Switzerland Krebsforschung Schweiz, Bern, Switzerland University Hospital Freiburg University Hospital, Zürich
Treatments:
LCZ 696 Sacubitril and valsartan sodium hydrate drug combination